Quarterly report pursuant to Section 13 or 15(d)

Restructuring Charges

v3.8.0.1
Restructuring Charges
3 Months Ended
Mar. 31, 2018
Restructuring And Related Activities [Abstract]  
Restructuring Charges

7. Restructuring Charges

On December 19, 2016, the Board of Directors approved a restructuring of the Company’s business based on its decision to focus the Company’s efforts on clinical development, with an initial focus on the X358 clinical programs. The restructuring included a reduction-in-force in which the Company terminated 57 employees. In early 2017, the Company further revised its strategy to prioritize out-licensing activities and further curtail research and development spending and terminated five additional employees.

The following table summarizes the accrued restructuring costs on the condensed consolidated balance sheet as of March 31, 2018 (in thousands):

 

 

 

Employee

Severance

 

 

 

and Other

Benefits

 

Balance at December 31, 2016

 

$

3,594

 

Restructuring charges

 

 

3,447

 

Cash payments

 

 

(6,911

)

Balance at December 31, 2017

 

 

130

 

Cash payments

 

 

(130

)

Balance at March 31, 2018

 

$